LRMR vs PTCT
LRMR: Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia. PTCT: PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved products and partnered collaboration deals.
Side-by-side fundamentals
| Metric | LRMR | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.02 | $78.40 | |
| Market cap as of 2026-07-23 | $418M | $6.5B | |
| P/E as of 2026-07-23 | n/a | 881.48 | |
| PEG as of 2026-07-23 | -0.05 | 1.20 | LRMR lower |
| Net margin as of 2026-07-23 | n/a | +0.9% | |
| Gross margin as of 2026-07-23 | n/a | +32.6% | |
| Operating margin as of 2026-07-23 | n/a | +8.9% | |
| ROE as of 2026-07-23 | -134.1% | +0.1% | PTCT higher |
| ROA as of 2026-07-23 | -96.0% | +0.3% | PTCT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.03 | LRMR lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -53.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.3% | |
| Beta as of 2026-07-23 | 0.76 | 0.54 | |
| 1-year return as of 2026-07-22 close | +18.9% | +69.0% | PTCT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.